Bin-Jin Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bin-Jin Hwang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Amy Hobeika
Department of Surgery, Duke University, Durham, NC, USA
1 shared publication Bushanqing Liu
Department of Surgery, Duke University, Durham, NC, USA
1 shared publicationCong-Xiao Liu
Department of Surgery, Duke University, Durham, NC, USA
1 shared publicationDavid T. Severson
Department of Surgery, Duke University, Durham, NC, USA
1 shared publicationElishama Kanu
Department of Surgery, Duke University, Durham, NC, USA
1 shared publication- Erika J. Crosby
Department of Surgery, Duke University Medical Center, Durham, NC 27701, USA
1 shared publication
Latest Publications
- 19 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (114) , eadz2294
CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity
Tumor antigen vaccination represents an appealing approach for cancer but has failed to materialize as oncologic standard of care. To understand long-term vaccine efficacy, we conducted a retrospective analysis of patients with human epidermal growth receptor 2 + (HER2 + ) breast cancer who received HER2-targeting vaccines and survived for >18 years. PBMC analysis revealed HER2-specific CD27 + memory CD4 and CD8 T cells, suggesting that CD27 signaling supports long-term immune memory. In human CD27 transgenic mice, combining HER2 vaccination with anti-CD27 agonism enhanced HER2-specific responses, particularly long-lived CD4 memory T cells. Murine models demonstrated ~40% tumor regression with combined therapy compared with vaccine alone (~6%). Additional scRNA-seq analysis identified CD4 T cells with a distinct gene expression profile, and depletion/adoptive transfer studies validated that CD4 T cells were essential for this effect. These findings suggest that CD27 agonism enhances vaccine-induced antigen-specific CD4 T cell responses, enabling durable antitumor immunity not entirely dependent on CD8 T cells.
- 19 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (114) , eadz2294
CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity
Tumor antigen vaccination represents an appealing approach for cancer but has failed to materialize as oncologic standard of care. To understand long-term vaccine efficacy, we conducted a retrospective analysis of patients with human epidermal growth receptor 2 + (HER2 + ) breast cancer who received HER2-targeting vaccines and survived for >18 years. PBMC analysis revealed HER2-specific CD27 + memory CD4 and CD8 T cells, suggesting that CD27 signaling supports long-term immune memory. In human CD27 transgenic mice, combining HER2 vaccination with anti-CD27 agonism enhanced HER2-specific responses, particularly long-lived CD4 memory T cells. Murine models demonstrated ~40% tumor regression with combined therapy compared with vaccine alone (~6%). Additional scRNA-seq analysis identified CD4 T cells with a distinct gene expression profile, and depletion/adoptive transfer studies validated that CD4 T cells were essential for this effect. These findings suggest that CD27 agonism enhances vaccine-induced antigen-specific CD4 T cell responses, enabling durable antitumor immunity not entirely dependent on CD8 T cells.